Review



anti ps6 s235 236  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc anti ps6 s235 236
    Anti Ps6 S235 236, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1980 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti ps6 s235 236/product/Cell Signaling Technology Inc
    Average 98 stars, based on 1980 article reviews
    anti ps6 s235 236 - by Bioz Stars, 2026-02
    98/100 stars

    Images



    Similar Products

    anti ps6 s235 236  (Cell Signaling Technology Inc)
    98
    Cell Signaling Technology Inc anti ps6 s235 236
    Anti Ps6 S235 236, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti ps6 s235 236/product/Cell Signaling Technology Inc
    Average 98 stars, based on 1 article reviews
    anti ps6 s235 236 - by Bioz Stars, 2026-02
    98/100 stars
    		  Buy from Supplier
    ps6 s235 236 cell signaling 2211 rrid ab 331679 1 100  (Cell Signaling Technology Inc)
    98
    Cell Signaling Technology Inc ps6 s235 236 cell signaling 2211 rrid ab 331679 1 100
    Inhibition of the mTOR pathway in PNs reduces Pvalb specification (A) Experimental design: Chimeric cortical organoids were treated with either 250 nM Rapamycin or a vehicle (control) starting at the time of grafting and continuing for 14 days. (B) Representative images and quantification of phosphorylated ribosomal <t>protein</t> <t>S6</t> <t>(pS6)</t> in both control and rapamycin-treated organoids at 14 DPG. White arrows indicate INs positive for both td-Tomato and pS6. Scale bar, 10 μm. n = 245 cells for control organoids and n = 342 cells for rapamycin-treated organoids. (C) Comparison of IN subtypes in control versus Rapamycin-treated organoids. Scale bar, 10 μm. n = 182 for control organoids and n = 210 for rapamycin-treated organoids. Unpaired parametric Student’s t test without Welch’s correction: ∗∗ = p < 0.01; ∗∗∗ = p < 0.001. Error bars represent SEM. See also <xref ref-type=Figures S13–S17 . " width="250" height="auto" />
    Ps6 S235 236 Cell Signaling 2211 Rrid Ab 331679 1 100, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ps6 s235 236 cell signaling 2211 rrid ab 331679 1 100/product/Cell Signaling Technology Inc
    Average 98 stars, based on 1 article reviews
    ps6 s235 236 cell signaling 2211 rrid ab 331679 1 100 - by Bioz Stars, 2026-02
    98/100 stars
    		  Buy from Supplier
    ps6 s235 236  (Cell Signaling Technology Inc)
    98
    Cell Signaling Technology Inc ps6 s235 236
    A Luminex assay of lysates from control and TTFields-treated (72 h) U-87 MG and A2780 cells. Left panel: heatmap showing the log fold change of phosphorylated to total protein ratio relative to the control. Right panel: AKT phosphorylation (Ser473) is presented as mean ± SEM; N ≥ 2 . * p < 0.05; ** p < 0.01; multiple unpaired t-tests. B – D Western blot analysis of AKT, pAKT (Ser473), BAD, pBAD (Ser136), and GAPDH in lysates from control and TTFields-treated (72 h) U-87 MG, A2780, and H1299 cells. Densitometric analysis for phosphorylation fold change is shown as mean ± SEM; N ≥ 3. * p < 0.05, ** p < 0.01, and *** p < 0.001; multiple unpaired t-tests. E – I Western blot analysis of AKT, pAKT (Thr308), ULK1, pULK1 (Ser757), S6, <t>pS6</t> (Ser235/236), 4EBP1, 4EBP1 (Thr37/46), and GAPDH in lysates from control and TTFields-treated (72 h) U-87 MG, A2780, and H1299 cells. Densitometric analysis for phosphorylation fold change is shown as mean ± SEM; N ≥ 3. * p < 0.05, ** p < 0.01, and *** p < 0.001; multiple unpaired t -tests. J Immunohistochemical analysis of pAKT (Ser473) in tumor sections from control and TTFields-treated animals: N1-S1 hepatocellular carcinoma (HCC) tumors (150 kHz, 5 days), MOSE-L ovarian cancer tumors (200 kHz, 10 days), and LL/2 lung tumors (150 kHz, 8 days). Representative images and quantification performed as an average of 5 images per animal, shown as mean ± SD with a total of 7–13 animals per group. ** p < 0.01; multiple unpaired t -tests.
    Ps6 S235 236, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ps6 s235 236/product/Cell Signaling Technology Inc
    Average 98 stars, based on 1 article reviews
    ps6 s235 236 - by Bioz Stars, 2026-02
    98/100 stars
    		  Buy from Supplier
    anti ps6 s235  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc anti ps6 s235
    A Luminex assay of lysates from control and TTFields-treated (72 h) U-87 MG and A2780 cells. Left panel: heatmap showing the log fold change of phosphorylated to total protein ratio relative to the control. Right panel: AKT phosphorylation (Ser473) is presented as mean ± SEM; N ≥ 2 . * p < 0.05; ** p < 0.01; multiple unpaired t-tests. B – D Western blot analysis of AKT, pAKT (Ser473), BAD, pBAD (Ser136), and GAPDH in lysates from control and TTFields-treated (72 h) U-87 MG, A2780, and H1299 cells. Densitometric analysis for phosphorylation fold change is shown as mean ± SEM; N ≥ 3. * p < 0.05, ** p < 0.01, and *** p < 0.001; multiple unpaired t-tests. E – I Western blot analysis of AKT, pAKT (Thr308), ULK1, pULK1 (Ser757), S6, <t>pS6</t> (Ser235/236), 4EBP1, 4EBP1 (Thr37/46), and GAPDH in lysates from control and TTFields-treated (72 h) U-87 MG, A2780, and H1299 cells. Densitometric analysis for phosphorylation fold change is shown as mean ± SEM; N ≥ 3. * p < 0.05, ** p < 0.01, and *** p < 0.001; multiple unpaired t -tests. J Immunohistochemical analysis of pAKT (Ser473) in tumor sections from control and TTFields-treated animals: N1-S1 hepatocellular carcinoma (HCC) tumors (150 kHz, 5 days), MOSE-L ovarian cancer tumors (200 kHz, 10 days), and LL/2 lung tumors (150 kHz, 8 days). Representative images and quantification performed as an average of 5 images per animal, shown as mean ± SD with a total of 7–13 animals per group. ** p < 0.01; multiple unpaired t -tests.
    Anti Ps6 S235, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti ps6 s235/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    anti ps6 s235 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibition of the mTOR pathway in PNs reduces Pvalb specification (A) Experimental design: Chimeric cortical organoids were treated with either 250 nM Rapamycin or a vehicle (control) starting at the time of grafting and continuing for 14 days. (B) Representative images and quantification of phosphorylated ribosomal protein S6 (pS6) in both control and rapamycin-treated organoids at 14 DPG. White arrows indicate INs positive for both td-Tomato and pS6. Scale bar, 10 μm. n = 245 cells for control organoids and n = 342 cells for rapamycin-treated organoids. (C) Comparison of IN subtypes in control versus Rapamycin-treated organoids. Scale bar, 10 μm. n = 182 for control organoids and n = 210 for rapamycin-treated organoids. Unpaired parametric Student’s t test without Welch’s correction: ∗∗ = p < 0.01; ∗∗∗ = p < 0.001. Error bars represent SEM. See also <xref ref-type=Figures S13–S17 . " width="100%" height="100%">

    Journal: iScience

    Article Title: Fate plasticity of interneuron specification

    doi: 10.1016/j.isci.2025.112295

    Figure Lengend Snippet: Inhibition of the mTOR pathway in PNs reduces Pvalb specification (A) Experimental design: Chimeric cortical organoids were treated with either 250 nM Rapamycin or a vehicle (control) starting at the time of grafting and continuing for 14 days. (B) Representative images and quantification of phosphorylated ribosomal protein S6 (pS6) in both control and rapamycin-treated organoids at 14 DPG. White arrows indicate INs positive for both td-Tomato and pS6. Scale bar, 10 μm. n = 245 cells for control organoids and n = 342 cells for rapamycin-treated organoids. (C) Comparison of IN subtypes in control versus Rapamycin-treated organoids. Scale bar, 10 μm. n = 182 for control organoids and n = 210 for rapamycin-treated organoids. Unpaired parametric Student’s t test without Welch’s correction: ∗∗ = p < 0.01; ∗∗∗ = p < 0.001. Error bars represent SEM. See also Figures S13–S17 .

    Article Snippet: • Rabbit anti-Bdnf (Abcam # ab108319; RRID: AB_10862052 ; 1:100) • Rat anti-Bcl11b (Abcam # ab18465; RRID: AB_2064130 ; 1:100) • Rabbit anti-Cox6A2 (Novus Biologicals # NBP1-31112; RRID: AB_2085447 ; 1:100) • Mouse anti-ErbB4 (Thermo Fisher Scientific # MA5-12888; RRID: AB_10986112 ; 1:100) • Rabbit anti-Gbx2 (Proteintech # 21639-1-AP; RRID: AB_2878896 ; 1:250) • Goat anti-eGFP (Abcam # ab6658; RRID: AB_305631 ; 1:100) • Mouse anti-HNA (Millipore Sigma # MAB1281; RRID: AB_94090 ; 1:100) • Rabbit anti-Map2 (Proteintech # 17490-1-AP; RRID: AB_2137880 ; 1:100) • Rabbit anti-MAPK (ERK1/2) phosphorylated (T202/Y204) (Cell Signaling # 9101; RRID: AB_331646 ; 1:100) • Rabbit anti-Mef2c (Abcam # ab227085; RRID: AB_3080861 ; 1:250) • Mouse anti-Mki67 (BD Biosciences # 550609; RRID: AB_393778 ; 1:600) • Mouse anti-Nestin (Thermo Fisher Scientific # MA1-110; RRDI: AB_2536821 ; 1:1000) • Rabbit anti-Nkx2.1 (Abcam # ab76013; RRID: AB_1310784 ; 1:100) • Mouse anti-Nr2f2 (R&D Systems # PP-H7147-00; RRID: AB_2155627 ; 1:100) • Rabbit anti-Pvalb (Swant # PV27; RRID: AB_2631173 ; 1:250) • Rabbit anti-Psd95 (Thermo Fisher Scientific # 51-6900; RRID: AB_2533914 ; 1:100) • Chicken anti-Rbfox3 (NeuN) (Millipore Sigma # ABN91; RRID: AB_11205760 ; 1:200) • Chicken anti-RFP (Rockland Immunochemicals # 600-901-379; RRID: AB_10704808 ; 1:100) • Rabbit anti-S6 phosphorylated (pS6) (S235/236) (Cell Signaling # 2211; RRID: AB_331679 ; 1:100) • Mouse anti-Satb2 (Abcam # ab51502; RRID: AB_882455 ; 1:100) • Mouse anti-Sox2 (Santa Cruz Biotechnology # sc-365823; RRID: AB_10842165 ; 1:500) • Mouse anti-Sst (Santa Cruz Biotechnology # sc55565; RRID: AB_831726 ; 1:100) • Mouse anti-Tcf7l2 (Millipore Sigma # 05-511; RRID: AB_309772 ; 1:250)

    Techniques: Inhibition, Control, Comparison

    Journal: iScience

    Article Title: Fate plasticity of interneuron specification

    doi: 10.1016/j.isci.2025.112295

    Figure Lengend Snippet:

    Article Snippet: • Rabbit anti-Bdnf (Abcam # ab108319; RRID: AB_10862052 ; 1:100) • Rat anti-Bcl11b (Abcam # ab18465; RRID: AB_2064130 ; 1:100) • Rabbit anti-Cox6A2 (Novus Biologicals # NBP1-31112; RRID: AB_2085447 ; 1:100) • Mouse anti-ErbB4 (Thermo Fisher Scientific # MA5-12888; RRID: AB_10986112 ; 1:100) • Rabbit anti-Gbx2 (Proteintech # 21639-1-AP; RRID: AB_2878896 ; 1:250) • Goat anti-eGFP (Abcam # ab6658; RRID: AB_305631 ; 1:100) • Mouse anti-HNA (Millipore Sigma # MAB1281; RRID: AB_94090 ; 1:100) • Rabbit anti-Map2 (Proteintech # 17490-1-AP; RRID: AB_2137880 ; 1:100) • Rabbit anti-MAPK (ERK1/2) phosphorylated (T202/Y204) (Cell Signaling # 9101; RRID: AB_331646 ; 1:100) • Rabbit anti-Mef2c (Abcam # ab227085; RRID: AB_3080861 ; 1:250) • Mouse anti-Mki67 (BD Biosciences # 550609; RRID: AB_393778 ; 1:600) • Mouse anti-Nestin (Thermo Fisher Scientific # MA1-110; RRDI: AB_2536821 ; 1:1000) • Rabbit anti-Nkx2.1 (Abcam # ab76013; RRID: AB_1310784 ; 1:100) • Mouse anti-Nr2f2 (R&D Systems # PP-H7147-00; RRID: AB_2155627 ; 1:100) • Rabbit anti-Pvalb (Swant # PV27; RRID: AB_2631173 ; 1:250) • Rabbit anti-Psd95 (Thermo Fisher Scientific # 51-6900; RRID: AB_2533914 ; 1:100) • Chicken anti-Rbfox3 (NeuN) (Millipore Sigma # ABN91; RRID: AB_11205760 ; 1:200) • Chicken anti-RFP (Rockland Immunochemicals # 600-901-379; RRID: AB_10704808 ; 1:100) • Rabbit anti-S6 phosphorylated (pS6) (S235/236) (Cell Signaling # 2211; RRID: AB_331679 ; 1:100) • Mouse anti-Satb2 (Abcam # ab51502; RRID: AB_882455 ; 1:100) • Mouse anti-Sox2 (Santa Cruz Biotechnology # sc-365823; RRID: AB_10842165 ; 1:500) • Mouse anti-Sst (Santa Cruz Biotechnology # sc55565; RRID: AB_831726 ; 1:100) • Mouse anti-Tcf7l2 (Millipore Sigma # 05-511; RRID: AB_309772 ; 1:250)

    Techniques: Virus, Plasmid Preparation, Recombinant, Membrane, Imaging, RNA Sequencing, Software, Cell Culture, Modification, Knock-Out, Passaging

    A Luminex assay of lysates from control and TTFields-treated (72 h) U-87 MG and A2780 cells. Left panel: heatmap showing the log fold change of phosphorylated to total protein ratio relative to the control. Right panel: AKT phosphorylation (Ser473) is presented as mean ± SEM; N ≥ 2 . * p < 0.05; ** p < 0.01; multiple unpaired t-tests. B – D Western blot analysis of AKT, pAKT (Ser473), BAD, pBAD (Ser136), and GAPDH in lysates from control and TTFields-treated (72 h) U-87 MG, A2780, and H1299 cells. Densitometric analysis for phosphorylation fold change is shown as mean ± SEM; N ≥ 3. * p < 0.05, ** p < 0.01, and *** p < 0.001; multiple unpaired t-tests. E – I Western blot analysis of AKT, pAKT (Thr308), ULK1, pULK1 (Ser757), S6, pS6 (Ser235/236), 4EBP1, 4EBP1 (Thr37/46), and GAPDH in lysates from control and TTFields-treated (72 h) U-87 MG, A2780, and H1299 cells. Densitometric analysis for phosphorylation fold change is shown as mean ± SEM; N ≥ 3. * p < 0.05, ** p < 0.01, and *** p < 0.001; multiple unpaired t -tests. J Immunohistochemical analysis of pAKT (Ser473) in tumor sections from control and TTFields-treated animals: N1-S1 hepatocellular carcinoma (HCC) tumors (150 kHz, 5 days), MOSE-L ovarian cancer tumors (200 kHz, 10 days), and LL/2 lung tumors (150 kHz, 8 days). Representative images and quantification performed as an average of 5 images per animal, shown as mean ± SD with a total of 7–13 animals per group. ** p < 0.01; multiple unpaired t -tests.

    Journal: Cell Death & Disease

    Article Title: Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields)

    doi: 10.1038/s41419-025-07546-8

    Figure Lengend Snippet: A Luminex assay of lysates from control and TTFields-treated (72 h) U-87 MG and A2780 cells. Left panel: heatmap showing the log fold change of phosphorylated to total protein ratio relative to the control. Right panel: AKT phosphorylation (Ser473) is presented as mean ± SEM; N ≥ 2 . * p < 0.05; ** p < 0.01; multiple unpaired t-tests. B – D Western blot analysis of AKT, pAKT (Ser473), BAD, pBAD (Ser136), and GAPDH in lysates from control and TTFields-treated (72 h) U-87 MG, A2780, and H1299 cells. Densitometric analysis for phosphorylation fold change is shown as mean ± SEM; N ≥ 3. * p < 0.05, ** p < 0.01, and *** p < 0.001; multiple unpaired t-tests. E – I Western blot analysis of AKT, pAKT (Thr308), ULK1, pULK1 (Ser757), S6, pS6 (Ser235/236), 4EBP1, 4EBP1 (Thr37/46), and GAPDH in lysates from control and TTFields-treated (72 h) U-87 MG, A2780, and H1299 cells. Densitometric analysis for phosphorylation fold change is shown as mean ± SEM; N ≥ 3. * p < 0.05, ** p < 0.01, and *** p < 0.001; multiple unpaired t -tests. J Immunohistochemical analysis of pAKT (Ser473) in tumor sections from control and TTFields-treated animals: N1-S1 hepatocellular carcinoma (HCC) tumors (150 kHz, 5 days), MOSE-L ovarian cancer tumors (200 kHz, 10 days), and LL/2 lung tumors (150 kHz, 8 days). Representative images and quantification performed as an average of 5 images per animal, shown as mean ± SD with a total of 7–13 animals per group. ** p < 0.01; multiple unpaired t -tests.

    Article Snippet: Electrophoresis was performed on two different gels for each sample, one immunoblotted for total protein levels, and the other for the levels of the phosphorylated protein, using the following primary antibodies: 4E-BP1 (Cell Signaling, 9452), p4E-BP1 (Thr37/46) (Cell Signaling, 9459), AKT (Cell Signaling, 2920), pAKT (Ser473) (Cell Signaling, 4060), pAKT (Thr308) (Cell Signaling, 4056), AMPK (Cell Signaling, 2793), pAMPK (Thr172) (Cell Signaling, 2535), BAD (Abcam, ab32445), pBAD (Ser136) (Cell Signaling, 43665), FAK (Cell Signaling, 32855), pFAK (Tyr397) (Cell Signaling, 32835), GAPDH (Santa Cruz, sc-32233), GEF-H1 (Cell Signaling, 4145), pGEF-H1 (Ser886) (Cell Signaling, 14143), PI3K p85a (Cell Signaling, 13666), pPI3K p85 (Tyr458)/p55 (Tyr199) (Cell Signaling, 4228), N-cadherin (Abcam, ab18203), S6 (Cell Signaling, 4859), pS6 (S235/236) (Cell Signaling, 4858), ULK1 (Cell Signaling, 8054), pULK1 (Ser757) (Cell Signaling, 6888).

    Techniques: Luminex, Control, Phospho-proteomics, Western Blot, Immunohistochemical staining